Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada.
In: Journal of Oncology Pharmacy Practice, Jg. 27 (2021-07-01), Heft 5, S. 1189-1194
academicJournal
Zugriff:
Medication errors involving look alike sound alike (LASA) medications have widely been recognized to contribute to patient harm. Oncology biosimilars are considered to be LASA medications and require additional measures for operational safety. The Cancer Care Alberta (CCA) Pharmacy Educators developed an education strategy to ensure operational and patient safety during the implementation phase for oncology biosimilars in Alberta, Canada. This resulted in a smooth adoption of oncology biosimilars. As future oncology biosimilars are introduced, this framework will serve as the foundation to educate and train oncology pharmacy staff. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Education strategy for the implementation of oncology biosimilars essential for operational and patient safety in Alberta, Canada.
|
---|---|
Autor/in / Beteiligte Person: | Garg, Manju ; Chatterjee, Ashraf ; Chambers, Carole R |
Zeitschrift: | Journal of Oncology Pharmacy Practice, Jg. 27 (2021-07-01), Heft 5, S. 1189-1194 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 1078-1552 (print) |
DOI: | 10.1177/10781552211007535 |
Schlagwort: |
|
Sonstiges: |
|